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Simple Summary: The key factor in preventing premature death from cancer is an early and accurate
diagnosis. While common diagnostic procedures are successful in the detection and rough descrip-
tion of a tumor mass, a deeper insight into cancer’s molecular features is needed to optimize the
treatment and increase the chances of survival. Nanotechnology can aid the molecular diagnostics
of cancers through a design of nanomaterials that can simultaneously recognize specific cancer-
associated molecules, so-called tumor biomarkers, and allow for their visualization by different
imaging techniques. With a recent explosion in the production of various nanomaterials, the selection
of the most suitable nanomaterial for tumor biomarker detection becomes a challenge. In this article,
we review recent advances in the molecular diagnostics of cancer using nanotechnology and focus
on liganded noble metal quantum nanoclusters, a class of ultrasmall nanomaterials with distinctive
structural and optical properties, as tools in tumor biomarker detection.
Abstract: Cancer is one of the leading causes of premature death, and, as such, it can be prevented
by developing strategies for early and accurate diagnosis. Cancer diagnostics has evolved from the
macroscopic detection of malignant tissues to the fine analysis of tumor biomarkers using personal-
ized medicine approaches. Recently, various nanomaterials have been introduced into the molecular
diagnostics of cancer. This has resulted in a number of tumor biomarkers that have been detected
in vitro and in vivo using nanodevices and corresponding imaging techniques. Atomically precise
ligand-protected noble metal quantum nanoclusters represent an interesting class of nanomaterials
with a great potential for the detection of tumor biomarkers. They are characterized by high bio-
compatibility, low toxicity, and suitability for controlled functionalization with moieties specifically
recognizing tumor biomarkers. Their non-linear optical properties are of particular importance
as they enable the visualization of nanocluster-labeled tumor biomarkers using non-linear optical
techniques such as two-photon-excited fluorescence and second harmonic generation. This article re-
views liganded nanoclusters among the different nanomaterials used for molecular cancer diagnosis
and the relevance of this new class of nanomaterials as non-linear optical probe and contrast agents.
Keywords: tumor biomarker; cancer diagnostics; molecular diagnostics of cancer; liganded noble
metal quantum nanocluster; precision medicine; bioimaging; contrast agents; nonlinear optics;
two-photon-excited fluorescence
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1. Cancer Diagnostics and Nanotechnology
1.1. Cancer Diagnostics: From Macroscopic Description to Molecular Diagnostics and
Precision Medicine
Cancer is one of the leading causes of premature death globally [1]. In 2020, the
GLOBOCAN online database estimated almost 10 million cancer deaths in 185 countries
for 36 types of cancer [2]. Furthermore, cancer patients with comorbidities have higher
chances of dying from non-cancer-related causes [3], which further increases the overall
health and economic impact of cancer. So far, the most efficient strategy to reduce cancer
mortality and comorbidity rates and, consequently, the associated burden on the health care
system has been the early detection and diagnosis of cancer. However, despite tremendous
efforts, the early detection of cancer remains challenging, mainly due to the complex nature
of cancer. Moreover, fine features of specific tumors, which can be instructional in designing
and customizing therapeutic approaches, often escape standard diagnostic procedures.
Traditionally, clinicians have been able to reveal the presence of cancer only upon the
development of the first symptoms, which usually happens after a tumor mass has reached
a substantial size or even after the spreading of metastases. Samples of such tumors can be
extracted by tissue biopsies and characterized using standardized histopathological tech-
niques that enable the rough description and categorization of cancer cells. Nevertheless,
as biopsies are limited to small amounts of cancer tissue, this procedure provides little
information about the overall heterogeneity of cancers. Moreover, such invasive tissue
sampling cannot be performed repeatedly as it may inflict complications [4].
Some limitations of tissue biopsies have been overcome by the development of imaging
approaches, whereby entire tumors are visualized in situ. The foundations laid more
than a century ago by the discovery of X-rays [5] have allowed for the development of
techniques such as X-ray computed tomography (CT), positron emission tomography
(PET), single-photon emission computed tomography (SPECT), and magnetic resonance
imaging (MRI) (Table 1). These methods have an improved diagnostic capacity relative
to tissue biopsy as they can provide information about cancer processes, location, and
stage [6]. In particular, anatomy-based imaging (CT and MRI) provides information about
the location, size, and morphology of the cancer, and function-based imaging (PET and
SPECT) map physiological and biological processes within the cancer. Combining anatomy-
based imaging with function-based imaging further increases diagnostic power. The
introduction of hybrid imaging such as SPECT/CT, PET/CT, optical/CT, and PET/MRI has
improved diagnostic accuracy in oncology, but equipment and operational costs account for
their slow implementation [7]. Another imaging approach, optical molecular imaging, is
holding great promise for cancer diagnosis. Optical imaging (OI) can currently reach wide
spatial imaging scales, ranging from cells to organ systems, which renders this technology
extremely appealing for medical imaging. Moreover, OI has at its disposal diverse contrast
mechanisms (using light absorption and emission methods as well as hybrid OI approaches)
for distinguishing normal from pathologic processes and tissues in both small animal and
human studies. Typically, complex methods are needed to extract quantitative data from
deep tissues.
In the 1970s, with the development of nuclear medicine and the application of ra-
dioisotope tracers that are internalized by cancer cells [8], the focus shifted to the molecular
events associated with cancer. An example of such an approach is the application of 2-
18F-fluorodeoxyglucose (FDG), a glucose analog whose accumulation increases in cancer
cells relying on glucose metabolism [9,10]. FDG is still extensively used for detection by
PET imaging of various cancers, including breast and colorectal cancers, melanomas, and
lymphomas. However, FDG labeling has limited specificity since non-cancer cells can also
metabolize glucose. The need for increased specificity has prompted a search for new
tumor-specific entities, with the goal to develop reliable detection strategies that will aid
the early detection of cancer.
The shift towards the molecular profiling of cancer in the late 20th century has paved
a road to a precision medicine approach where molecular profiling is combined with
Cancers 2021, 13, 4206 3 of 28
large biomedical data sets and used for precision diagnostics, prognostics, and therapeutic
strategies in the cancer field [11]. A fundamental goal of precision medicine is to provide
effective therapeutic strategies for patients based on their individual cellular, molecular,
and biomarker characteristics, along with their unique genetic and environmental fac-
tors [12]. Hence, the terms “precision medicine” and “personalized medicine” are often
used interchangeably. This approach is driven by technological advances, the interpretation
of -omics data, and the development of targeted therapies based on the identification of
tumor biomarkers [13,14].
Table 1. Techniques used for cancer diagnosis.
Diagnostic Method Principle Technique Detection Agent/Visualization
Imaging
Function-based PET Radioactive tracers that producepositrons/Scanner
Function-based SPECT Radioactive tracers that emit gammarays/Scanner
Anatomy-based MRI Magnet, radiofrequency/Scanner
Anatomy-based CT X-ray/Scanner
Hybrid (anatomy- and function-based) PET/CT, PET/MRI, SPECT/CT Combination of radioactive tracer and imagingmodality
Optical PA, SERS Luminescent probe/Scanner
Molecular diagnostics
Gene amplification PCR DNA sequencing
Cytogenetic analysis—hybridization of nucleic
acids in cells/tissues FISH Fluorescent labels/Fluorescent microscopy
Hybridization of nucleic acids in microplates DNA microarrays Labels/Microscopy
Immunoassay for protein detection ELISA Luminescent probe/Plate reader
Tumor biomarkers are specific entities produced by cancer cells that can be found in
the tumor itself or in the tissues and body fluids of patients. Altered levels of a wide range
of entities, such as cells, proteins, peptides, post-translational modifications, metabolites,
nucleic acids, and genetic variations, can reveal the presence of cancer in the body as
well as help in individualized risk factor assessments, prognostics, and therapy response
prediction [15]. Additionally, monitoring patients’ response to treatment can identify
molecular alterations occurring during treatment and help navigate the course of the
therapy. For instance, genomic alternations such as specific mutations in breast cancer
1 (BRCA1) and breast cancer 2 (BRCA2) genes are well-established tumor biomarkers
used for breast cancer risk assessment, meaning that women bearing these mutations are
predisposed to develop breast cancer [16,17]. Moreover, it has been shown that the BRCA
status predicts the responsiveness to therapies that interfere with DNA repair machinery,
such as cisplatin or olaparib [18,19]; in particular, patients that do not bear these specific
mutations are unlikely to respond to such treatments. Hence, unnecessary exposure to toxic
therapies can be avoided by genotyping patients. This example highlights the complexity
of cancer and the need for the discovery of effective tumor biomarkers that will help in
achieving the goals of precision medicine and allow the stratification of patients.
1.2. Methods in Molecular Diagnostics of Cancer
The development of methods for analysis and the monitoring of the tumor biomarker
landscape during tumorigenesis is of great importance for accurate cancer diagnostics
and the design of personalized therapeutic options. Indeed, the introduction of genomics,
epigenetics, proteomics, metabolomics, informatics, and imaging techniques has greatly
improved our understanding of cancer’s molecular features and allowed for improved
survival prospects for patients by matching tumor characteristics with complementary
therapy [20]. These methods are applicable to the analyses of tumor tissue biopsies as well
as liquid biopsies, which contain biomarkers released by the tumor into bodily fluids, such
as circulating tumor nucleic acids and circulating tumor cells (CTC) [21,22].
At present, the characterization of the cancer genome is performed by polymerase
chain reaction (PCR) assays, high-throughput DNA microarrays, or fluorescence in situ
hybridization (FISH) [23,24]. These techniques enabled the detection of short tandem
repeats [25], loss of heterozygosity [26], alterations in DNA methylation status, and various
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mutations. For instance, sequencing for genetic alterations in human epidermal growth
factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), vascular en-
dothelial growth factor (VEGFR), rearranged during transfection (RET) tyrosine kinase,
mesenchymal–epithelial transition factor (MET), mitogen-activated protein kinase (MEK),
anaplastic lymphocyte kinase (ALK), and ROS proto-oncogene 1 (ROS1) has allowed for
precision therapy of non-small cell lung cancer, liver cancer, breast cancer, and renal cell
carcinoma based on matching the individual’s cancer mutations with a specific tyrosine
kinase inhibitor as a treatment of choice [27,28].
Specific detection and identification of protein biomarkers in clinics have been mainly
accomplished by various immunological techniques based on labeling sensors, where the
final result is proportional to the amount of label bound to the targeted molecule [29,30].
The enzyme-linked immunosorbent assay (ELISA) is widely used for protein detection and
quantification and is based on the use of specific binding surfaces decorated with antibodies
that capture protein biomarkers from various body fluids. Protein biomarkers are then
revealed by enzyme-labeled antibodies [31] that produce a fluorescent signal/color that
corresponds to the amount of biomarker immobilized by the capturing antibody. ELISA
displays high sensitivity–for instance, it can already detect the prostate-specific antigen
(PSA), which is used for prostate cancer screening, at a concentration of 100 pg/mL [32].
However, the use of a single cancer protein biomarker is not sufficient for accurate cancer
detection, as PSA can also be detected in patients with benign prostatic hyperplasia [33].
Therefore, to improve diagnostic accuracy, various multiplex immunoassays that combine
the antibody-labeled detection of different protein biomarkers are needed. An example of
a multiplex immunoassay is the FDA-approved OVA1® test that combines the detection of
multiple serum-derived protein cancer antigen 125 (CA 125), transferrin, apolipoprotein A-I
(APOA1), β2-microglobulin, and transthyretin with software calculations to predict ovarian
malignancy [34]. In the second generation OVA2® (Overa) test, the latter two-protein
biomarkers are replaced with human epididymis protein 4 (HE4) and follicle-stimulating
hormone (FSH), having improved accuracy and reduced false results [35,36]. Due to their
high sensitivity, immunological techniques are also used for the detection of CTC. For
example, the CellSearch® system uses nanoparticles labeled with antibodies that target the
epithelial cell adhesion molecule (EpCAM) to separate CTC from other cells present in the
blood of patients with metastatic colorectal, breast, or prostate cancer. Immunomagnetic
separation is followed by the immunocytological detection of various cytokeratins and
leukocyte common antigen CD45 as well as the analysis of the cellular nuclei using a
fluorescence microscope.
The recently developed CancerSEEK test [37] combines the multiplex measurement
of genetic alterations in ctDNA with the measurement of protein levels of CA 125, cancer
antigen 19-9 (CA 19-9), carcinoembryonic antigen (CEA), osteopontin (OPN), prolactin
(PRL), myeloperoxidase (MPO), tissue inhibitor of metalloproteinases 1 (TIMP1), and
hepatocyte growth factor (HGF) in blood samples. Through the measurement of ctDNA
and protein biomarkers, the CancerSEEK tumor biomarker detection test displays 69–98%
sensitivity in detecting liver, ovarian, stomach, esophageal, and pancreatic cancer.
1.3. Metallic Nanomaterials in Detection of Tumor Biomarkers
1.3.1. Nanotechnology in Cancer Diagnostics: From Large Nanoparticles (NPs) to
Nanoclusters (NCs)
Despite the progress in understanding cancer biology, the diagnostics of cancer still
faces many challenges [38]. Currently used clinical procedures are often invasive and un-
pleasant and have limited potential to detect specific molecular events [39]. Hence, there is
a great need to improve cancer diagnostics by developing tools that might complement the
existing clinical approaches or novel, non-invasive alternatives with enhanced specificity
and sensitivity.
In the past few decades, nano-sized devices have undergone rapid development due
to their immense potential in biomedical applications [40]. Their ability to act on a cellular
or subcellular level has prompted an enormous number of studies exploring a large panel
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of organic (liposomes, micelles, biopolymeric NPs, dendrimers) and inorganic (metal NPs,
quantum dots, carbon nanotubes, nanoshells, nanocrystals) nanomaterials. The versatility
of nanomaterials offers room for the optimization of their stability, selectivity, biological
targeting properties, and detection. Some nanomaterials have already been introduced to
(pre-)clinical cancer diagnostics, as is the case with iron oxide nanoparticles, which are used
as a contrast agent for MRI imaging [41,42]. Importantly, suitable surface modification of
nanomaterials enables their selective binding to a specific biological target, thus opening
opportunities for the expansion of use of metal-based nanomaterials in various therapeutic
and targeting systems [43].
Over the past few decades, various metal-based nanomaterials, composed of gold,
silver, or copper, have been synthesized for molecular imaging and drug delivery purposes.
Among all metallic nanomaterials, gold nanomaterials exhibit superior stability and optical
properties and generally have lower toxicity, which makes them good candidates for poten-
tial clinical applications in diagnostics and therapy [44] and, in particular, in personalized
medicine approaches.
Generally, metallic nanomaterials can be classified into three size groups: large NPs,
small NPs, and quantum nanoclusters (NCs) [45]. Large NPs are larger than 50 nm and can
be seen as small metal spheres [46], the optical properties of which depend on their volume
and dielectric constant. For the second group of small NPs, with the size of 2–50 nm, the
dielectric function becomes size-dependent, and the optical response is of a plasmonic
nature. Finally, NCs are drastically different due to their ultrasmall size (<2 nm) and
molecule-like properties, characterized by quantum discrete states. Of note, nanomaterial
solutions are often heterogeneous in terms of individual particle sizes as it is difficult
to achieve uniformity during synthesis, and, moreover, the agglomeration of individual
particles can occur [47]. Average uniformity is expressed as a polydispersity index (PDI)—
the square of the standard deviation of the particle diameter distribution divided by the
mean particle diameter. PDI reflects the quality of the nanomaterial solution, and it is
relevant to their clinical application.
1.3.2. Functionalization of Nanomaterials
The use of nanomaterials for cancer diagnostics is based on the functionalization of
their surface by various ligands that serve to (1) maintain their physicochemical properties
in vitro and in the biological environment (structural functionalization) and (2) provide
them with specific target-recognition properties (specializing functionalization) [48,49].
Structural functionalization is used to protect the metallic nanomaterial from harsh condi-
tions (such as suboptimal pH) as well as to reduce its toxicity and improve bioavailability.
Compounds containing sulfur, such as cysteine (Cys), glutathione (GSH), mercaptopropi-
onic acid (MPA), bidentate dihydrolipoic acid (DHLA), and thiolated polyethylene glycol
(PEG), are the most common ligands used for structural functionalization.
Specializing functionalization adds various recognition moieties to metallic nanoma-
terials, which makes them competent to efficiently detect specific molecular targets and
deliver drugs to desired destinations within the biological systems [50]. Those recognition
moieties include peptides, antibodies, proteins, aptamers, small molecules, or polymers,
and they enable the binding of functionalized nanomaterials to a specific tumor entity.
The resulting complex between a tumor entity and nanomaterial can then be detected by
suitable imaging techniques.
The addition of a recognition moiety can be achieved by a ligand exchange strat-
egy based on the replacement of a structural ligand with a specific biomolecule or by a
conjugation strategy that allows the binding of the molecule of interest to the structural
ligands on the metallic nanomaterial. The ligand substitution induces size and structure
transformation, and, generally, this approach is more difficult to apply on small NPs than
on NCs [51].
Conjugation is usually based on the activation of the carboxylic acid of the protec-
tive ligand with N-(3-dimethylaminopropyl)-N*-ethylcarbodiimide hydrochloride (EDC),
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which allows the formation of amide bonds between carboxyl groups of the ligand with
amine residues on the protein surface. One such example is the work of Jazayeri et al.,
where a PEGylated gold nanoparticle was conjugated with an anti-PSA antibody using
an EDC/N-hydroxylsuccinimide (NHS) linker [52]. The conjugation of antibodies such as
anti-EGFR [53] and anti-Her2 [54–56] is of particular interest as they are already in clinical
use for cancer detection and effective tumor targeting [57]. Over the recent years, the
addition of a variety of ligands by conjugation [58–62] has become the method of choice as
it offers tremendous opportunities in molecular recognition and targeting.
1.3.3. Tumor Biomarker Detection by Metallic Nanomaterials
In the past couple of decades, a number of metallic nanomaterials targeting various
tumor biomarkers have been developed (reviewed in [63–65]). Here, we summarize recent
examples of such nanomaterials, mostly metal NPs and NCs (Table 2). Many of them
recognize receptors overexpressed on the surface of malignant cells, including the folate
receptor, EGFR, HER2, GLUT, GRPR, and CCR5. Selection of the plasma-membrane-located
receptors as targets is a reasonable strategy in the design of nanomaterials as it increases
the probability that the nanomaterial will encounter the target and get internalized into
the cells. In such instances, specializing ligands are either the natural ligands (e.g., folic
acid for the folate receptor or glucose for GLUT) or peptides, aptamers, and antibodies
designed to specifically target the receptors.
Metallic nanomaterials bound to their molecular targets can be detected using multiple
techniques, the choice of which depends on the properties of the nanomaterial and the com-
patibility of these techniques with the type of nanomaterial-labeled biosample—cell line,
tissue, liquid biopsy, or the entire organism. While some nanomaterials, such as AuNCs,
are intrinsically luminescent in the range from visible to near-infrared (NIR) light [66,67],
others require adaptation to the desired detection method by functionalization. In cell
culture samples, such nanomaterials can be detected using fluorescence microscopy or
less common methods, such as inductively coupled plasma mass spectrometry (ICP-MS),
inductively coupled plasma atomic emission spectroscopy (ICP-AES), auto-metallography,
and surface-enhanced Raman spectroscopy (SERS) [56,68,69]. Nanomaterial-labeled liq-
uid biopsies (human serum and urine) allow the application of other methods such as
fluorescence spectroscopy, colorimetric detection, and surface plasmon resonance (SPR)
biosensors [70,71]. Finally, nanomaterials can be detected in vivo, e.g., in xenografted mice
using MRI, nuclear imaging methods (SPECT, PET/CT, autoradiography), NIR fluorescence
imaging systems, or photoacoustic imaging. For MRI, it is required for the nanomaterials
to include or to be coated with a heavy metal such as iron oxide or gadolinium [72,73]. On
the other hand, nuclear imaging methods require the labeling of the nanomaterials with
radioisotopes [74]. Among these techniques, relatively novel photoacoustic imaging has
been viewed as one of the most promising imaging techniques due to a relatively large
imaging depth (up to 1 cm) [75]. This non-invasive imaging modality uses the optical
properties of the nanomaterial and is compatible with both AuNPs and AuNCs [76–78].
Despite the huge variety of different nanomaterials developed for cancer diagnostics,
only a small number have progressed to clinical trials [64]. Currently, there are 27 nanopar-
ticles under clinical investigation for cancer diagnostics registered in clinicaltrials.gov.
Despite their potential for biomedical applications, there are still biological (e.g., biodistri-
bution, metabolism, pharmacokinetics), technological, safety, and regulatory challenges
that need to be thoroughly investigated [65].
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Table 2. Examples of cancer biomarker detection by different types of metallic nanomaterials.
Biomarker Detection Functionalization Nanoparticle/Nanocluster
Method Biomarker Model Type of Ligand Ligand Composition Dimension (nm) PDI Ref.
Fluorescence
microscopy
Folate receptor Lung, breast cancercell lines Small molecule Folic Acid Au25-BSA ~1/~8 (aggregates) - [58]
PrPc Colorectal cancer cellline Oligonucleotide PrPC aptamer AuNPs
13/20 (NPs/NPs +
PrPc) - [79]
EGFR Lung cancer celllines Protein EGFR-specific scFv Fe3O4/AuNPs
30/76.3 (NPs/NPs +
scFv) - [80]
HER2 Breast cancer celllines Peptide Anti-HER2 peptide
Fe3O4/AuNPs-
Cy5.5 ~12 0.08 [81]
- In vitro blood–brainbarrier model Amino acid L-Dopa AuNCs-SG 1.4 - [82]
CD44 receptor Lung, breast cancercell lines Glycosaminoglycans Hyaluronic acid
Au-SG-Graphene
oxide 2 - [83]
Glutathione Cervical, liver, coloncancer cell lines Protein Transferrin AuNCs 4.72 ± 0.5 - [84]
Methionine level Lung, liver, breastcancer cell lines Amino acid Methionine Au-MET-MPA 5.6 0.118 [85]
PD-L1 Colon cancer cell line Antibody anti-PD-L1 Ab AuNPs-PEG 40.0 ± 3.1 - [86]





Extracellular vesicle Exosome AuNPs 105 ± 10.1 (DLS) 0.430 ± 0.06 [88]
Neuron Rat Protein WGA-HRP AuNPs-MSA 5.2 ± 1.3 - [89]
Folate receptor Ovarian cancer cellline Small molecule Folic acid AuNCs-BSA 25 ± 12 (DLS) - [90]
Thyroid Thyroid carcinomacancer cell line Chemical element
127Iodine AuNCs-BSA-I127 6.4 (DLS) - [68]
Calreticulin Colon, breast cancercell lines Antibody Anti-calreticulin Ab AuNCs-MSA 2 - [91]
HER2 Breast cancer celllines Oligonucleotide Affibody-DNA AuNPs




HER2 Stomach cancer celllines Antibody Tmab AuNPs 85.39 ± 0.68 (DLS) - [93]
PSMA Prostate cancer celllines Peptide PSMA-1 AuNPs-PEG-Pc4
5.5 ± 0.4
(AuNPs-PEG) - [94]
Folate receptor Bone, cervical, lungcancer cell lines Small molecule Folic acid Au22SG18 1.4 - [95]
Leukemia cells Leukemia cancer cellline Oligonucleotide KH1C12 aptamer Fe3O4/AuNPs 26 - [72]
Cancers 2021, 13, 4206 8 of 28
Table 2. Cont.
Biomarker Detection Functionalization Nanoparticle/Nanocluster
Method Biomarker Model Type of Ligand Ligand Composition Dimension (nm) PDI Ref.
Colorimetric
MMP9 Colon cancer miceurine Peptide
Protease-cleavable















phosphatase Human serum Small molecule Pyridoxal phosphate AuNCs-BSA 1.95 - [99]






Peptide Protease-cleavablepeptide AuNCs-SG ~1.5 - [96]







AuNPs-PEG 87.35 ± 0.41 (DLS) 0.17 [56]
















(NCs/NCs + FA +
HER)
- [102]












Antibody Cetuximab AuNPs-PEG 78.3 ± 0.7 (DLS) - [103]
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Table 2. Cont.
Biomarker Detection Functionalization Nanoparticle/Nanocluster



















Antibody Anti-PSA Ab AuNPs-PEG 25 - [52]
SERS
CD19 Leukemia cancer cellline Antibody Anti-CD19 Ab
AuNPs-PEG-
MGITC 60 (DLS) - [105]
CEA Breast and lungcancer cell lines Antibody Anti-CEA Ab
AuNPs-Fe3O4-ATP-















60 (NPs alone) - [69]
MRI
EGFR Xenografted lungcancer mice Protein EGFR-specific scFv Fe3O4/AuNPs
30 (NPs alone)
76.3 (NPs + scFv) - [80]
Leukemia cells Leukemia cancer cellline Oligonucleotide KH1C12 aptamer Fe3O4/AuNPs 26 - [72]





HER2 Xenografted breastcancer mice Peptide Anti-HER2 peptide
Fe3O4/AuNPs-
Cy5.5 ~12 0.08 [81]
EGFR Xenografted lungcancer mice Protein EGFR-specific scFv Fe3O4/AuNPs
30 (NPs alone)
76.3 (NPs + scFv) - [80]





Amino acid Methionine AuNCs-MET-MPA 5.6 0.118 [85]
- Mouse - - AuNPs-SG-Au198 2.6 ± 0.3 - [107]
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Table 2. Cont.
Biomarker Detection Functionalization Nanoparticle/Nanocluster
Method Biomarker Model Type of Ligand Ligand Composition Dimension (nm) PDI Ref.







Chemical element 127Iodine AuNCs-BSA-I127 6.4 (DLS) - [68]
Folate receptor Mouse Small molecule Folic acid Au22SG18 1.4 - [95]
SPECT
- Mouse - - AuNPs-SG-Au198 2.6 ± 0.3 - [107]
CCR5 Xenografted breastcancer mice Peptide
D-Ala1-peptide
T-amide
199AuNPs-PEG 5 - [108]
PET/CT
LHRH receptor Xenografted lungcancer mice Peptide LHRH peptide AuNCs-HSA-I











Antibodies VHH 122 AbCetuximab AuNPs-PEG
28/42/45/63(DLS)







Antibody 5B1 antibody AuNPs-Zr89 34.86 (DLS) 0.27 [104]
- EGFR Colon cancer celllines Antibody Anti-EGFR Ab AuNPs 14.9 ± 1.23 - [109]
Auto-radiography CCR5 Xenografted breastcancer mice Peptide
D-Ala1-peptide
T-amide



















Peptides GRPR-targetingpeptides Au nanorod
8 ± 2 nm (W)/49 ± 8
nm (L) - [77]
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2. Potential of Quantum Nanoclusters as Non-Linear Optical Probes in Molecular
Diagnostics of Cancer
Given the variety of options for nanomaterials as well as for the specializing and
structural ligands, the choice of an optimal nanodevice in designing strategies for tumor
biomarker detection presents a challenge. In this section, we elaborate on opportunities
provided by optical molecular imaging as a technique for biomarker detection and gold
NCs as non-linear optical (NLO) probes. NCs are particularly interesting due to their
distinctive physicochemical properties. However, these unique properties of the NCs are
often poorly recognized in the literature, promoting the perception of the NCs as merely
a smaller version of NPs. Here, we emphasize the key physicochemical features of the
NCs, in particular those features responsible for their biocompatible optical properties that
might be relevant for their application in cancer diagnostics.
2.1. Non-Linear Optical Techniques and Nanomaterials
Optical molecular imaging is holding great promise in cancer diagnosis. However, a
critical issue for photo-induced imaging is the capability of light to penetrate tissues. Since
tissues such as blood, fat, and skin inherently interact with any incident light, leading to
light absorption and/or scattering, it is essential for OI to operate at wavelengths where
light attenuation is minimal. The first NIR (NIR-I) window, between 700 and 900 nm,
and, more interestingly, the second (NIR-II) window fulfill this requirement for biological
imaging (Figure 1a) [111]. Thus, any contrast agents with small optical gaps and, hence,
with absorption (and possibly emission) in the NIR-II (1000–1400 nm) are highly desired
(Figure 1b). For this purpose, a plethora of exogenous contrast agents has been developed,
including inorganic imaging contrast agents and organic probes [111]. However, a major
challenge concerns the elucidation of the biocompatibility, pharmacokinetics, and long-term
toxicological profiles of such NIR-II contrast agents.
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Figure 1. Optical imaging in biological samples. (a) Tissues such as skin, fat, and blood (oxygenated and deoxygenated)
attenuate light in a wavelength-d pendent ma ner due to absor tion and scattering. Attenuation is the lowest in the
first (NIR-I, 700–900 nm, shaded in pink) or second near-infrared window (NIR-II, 1000–1700 nm, shaded in grey). Image
adapted from [112] with permission from Springer Nature. (b,c) Strategies for reaching the NIR-I and NIR-II windows:
using chromophores with small optical gaps (b) or applying NLO techniques (SHG, THG, and TPEF) (c). Images adapted
from [113].
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As an alternative to using chromophores with small optical gaps, NLO techniques
such as second harmonic generation (SHG) and two-photon-excited fluorescence (TPEF)
can be exploited (Figure 1c) [114]. SHG is a phenomenon whereby two photons with the
same frequency get combined during interaction with a non-linear material, generating a
new photon with twice the energy of the initial photons while conserving the coherence of
interaction. TPEF is based on simultaneous excitation with two photons, followed by the
emission of light with shorter wavelengths, and it is an incoherent phenomenon involving
radiative absorption and re-emission. In both cases, the photon energy can match the
second (NIR-II) window for biological imaging due to the inherent multi-photon process.
Thanks to the complementary information that they can provide, as well as the enhanced
contrasts and improved resolution, SHG and TPEF have gained overwhelming popularity
among biologists and have emerged as promising tools in the field of pre-clinical and
clinical cancer research.
In particular, TPEF imaging has become popular in tissue imaging due to its advan-
tages of longer wavelength excitation (>1000 nm), which minimizes auto-fluorescence
and bleaching and allows for a higher 3D resolution and deep tissue imaging in com-
parison to one-photon fluorescent microscopy [115]. Moreover, a study performed by
Lianhuang Li et al. showed that TPEF combined with SHG helped in identifying early
gastric cancer by assessing cell size and collagen alternations without using exogenous
contrast agents [116]. Interestingly, the sensitivity of such NLO techniques can be dra-
matically enhanced using exogenous contrast agents with NLO properties. Some organic
dyes have already been applied in multi-photon imaging, but their performance has been
hampered due to their rapid photo-bleaching and limited two-photon absorption (TPA)
cross-sections [117]. Quantum dots might be a superior option for multi-photon imaging as
they display large two-photon absorption cross-sections [118], but their strong cytotoxicity
and photon-blinking behavior [119] limit their applicability. Designing highly efficient
second-order NLO-phores is largely a matter of the fine combination of a high density of
delocalized electrons in a symmetrical or unsymmetrical environment. Recent advances
in the field of nanotechnology have allowed for the development of nanostructures that
display higher diffusion through tissues along with high TPA cross-sections [113,120]. In
particular, as discussed below, NLO characteristics of liganded noble metal NCs and the
possibility of their functionalization with specific recognition moieties hold promise for the
integration of such NCs with tools of precision medicine that might help in early cancer
detection as well as the stratification of patients and the development of treatment options.
2.2. Quantum Nanoclusters—General Features
NCs are an extremely appealing family of nanomaterials, in particular for bio-imaging
applications. NCs are characterized by a small number of metal atoms (between a few and
hundreds of atoms) and by molecular-like discrete states for which strong fluorescence
might occur. The connection between their structural and optical properties arises in the
size regime, in which “each atom counts”, meaning that the removal or addition of a
single metal atom can substantially change structural and optical properties. However,
NCs have to be stabilized and protected from the environment in order to prevent their
degradation or aggregation. The protection of noble metal NCs from photo-dissociation by
inorganic matrices or solid gas has been used since 1987 [121]. Dickson et al. first reported
in 2002 [122] the role of organic scaffolds, e.g., DNA oligomers, in the synthesis of silver
NCs as both metal cluster protection and the key ingredient for enhancing NC emission
in the visible to NIR regime. This dual role of ligands is quite general and has found an
application in boosting the NLO properties of liganded gold and silver NCs.
A large variety of ligands, including amino acids, peptides, proteins, small organic
molecules, polymers, DNA, and dendrimers, can be used for the protection of NCs. Figure 2
illustrates different ways to form and stabilize NCs in solution [123,124]. Various ligand-
engineering strategies have been developed to enhance the emissive properties of NCs [67].
Among the large variety of ligand families, thiolated molecules are particularly suitable
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due to strong Au-S binding. Additionally, thiols can be found in organic ligands but also in
natural biomolecules such as peptides and proteins. AuNCs with an appropriate choice of
thiol-containing ligands present with extremely good stability and biocompatibility and
attractive emissive properties, i.e., strong emitted fluorescence. These properties authorize
in vitro and in vivo detection of thiolated NCs by multimodal imaging techniques. The
wavelength of NC luminescence can be tuned from near-ultraviolet (UV) to the IR region,
allowing their detection by X-ray CT, OI, MRI, or photoacoustic imaging. Importantly, NCs
demonstrate higher brightness and photo-stability in comparison to organics dyes, which
are prone to photobleaching [125].
Cancers 2021, 13, 4206 13 of 29 
 
 
silver NCs as both metal cluster protection and the key ingredient for enhancing NC emis-
sion in the visible to NIR regime. This dual role of ligands is quite general and has found 
an application in boosting the NLO properties of liganded gold and silver NCs.  
A large variety of ligands, including amino acids, peptides, proteins, small organic 
molecules, polymers, DNA, and dendrimers, can be used for the protection of NCs. Figure 
2 illustrates different ways to form and stabilize NCs in solution [123,124]. Various ligand-
engineering strategies have been developed to enhance the emissive properties of NCs 
[67]. Among the large variety of ligand families, thiolated molecules are particularly suit-
able due to strong Au-S binding. Additionally, thiols can be found in or ic ligands but 
also in natural biomolecules such as peptides a d proteins. AuNCs with an appr priate 
ch ice of thiol-containing liga ds present with extremely good stability and biocompati-
bility and attractive emissive properties, i.e., strong emitted fluorescence. These properties 
authorize in vitro and in vivo detection of thiolated NCs by multimodal imaging tech-
niques. The wavelength of NC luminescence can be tuned from near-ultraviolet (UV) to 
the IR region, allowing their detection by X-ray CT, OI, MRI, or photoacoustic imaging. 
Importantly, NCs demonstrate higher brightness and photo-stability in comparison to or-
ganics dyes, which are prone to photobleaching [125]. 
 
Figure 2. Metal nanoclusters protected with different scaffolds. 
The ligand selection is of key importance not only for optimizing the optical proper-
ties of the NCs but also for developing their targeting competency. NCs can be function-
alized during the initial synthesis by the addition of selected target-binding molecules 
directly on the surface of NCs, e.g., via covalent attachment (post-functionalization) or by 
ligand exchange after liganded NC synthesis if the target molecule of interest has a thiol 
group (see Section 2.4.3). Finally, sufficient biocompatibility with minimal toxicity is re-
quired to qualify any liganded NC as a good candidate for biomedical imaging. 
2.3. Biological Properties of AuNCs  
2.3.1. Cellular Uptake—Internalization Mechanisms and Cytotoxicity 
The cellular uptake of AuNCs has been studied in multiple cellular systems [126]. It 
has been shown that the internalization of NCs is energy-dependent [127,128] and relies 
Figure 2. etal nanoclusters protected with different scaffolds.
The ligand selection is of key importance not only for ptim zing the optical pro erti s
of the NCs but also for developing their argetin competency. NCs can be functionalized
during the i itial sy thesis by the addi ion of selected targe -binding molecules direct y
on the surface of NCs, e.g., via covalent att chment (post-functionalization) or by ligand
exchange after lig nded NC synthesis if the target molecule f int rest has a thiol group
(see Section 2.4.3). Finally, sufficient bio ompatibility with minimal toxicity is required to
qualify any liganded NC as a good candidate for biom dical imaging.
2.3. Biological Properties of AuNCs
2.3.1. Cellular Uptake—Internalization Mechanisms and Cytotoxicity
The cellular uptake of AuNCs has been studied in multiple cellular systems [126]. It
has been shown that the internalization of NCs is energy-dependent [127,128] and relies on
multiple endocytic mechanisms such as clathrin-mediated endocytosis and micropinocyto-
sis. The caveolin-mediated pathway is also involved, albeit to a lesser extent. Following
their uptake, AuNCs were ultimately transferred to the lysosomes and were not able to
reach the nucleus even after 24 h of incubation with the cells [127]. The time dimension of
AuNC uptake was studied in BaF3 cells using an AuNC biofunctionalized with an aptamer
to target the IL6 receptor [129]. This study has shown that the NCs were bound to the
cellular membrane after 10 min of incubation with the cells and were internalized into the
cells after an additional 10 min. The cellular uptake of AuNCs has also been demonstrated
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in an in vitro model of the blood–brain barrier (BBB) using an AuNC functionalized with
l-3,4-dihydroxyphenylalanine (L-Dopa) to target the brain and cross BBB [82].
The nature of the ligands may affect the cellular uptake of AuNCs. For instance, zwit-
terionic ligands seem to be more supportive of AuNC internalization than the PEGylated
ones in human-derived monocyte dendritic cells [130]. Similarly, MPA-liganded AuNCs
were taken up more efficiently than GSH-AuNCs in the normal human colon mucosal
epithelial cell line NCM460 [131].
Generally, the cellular uptake of nanomaterials depends on their size and cell type.
Controversial results exist about the efficiency of AuNC uptake relative to other nanomate-
rials. For instance, the internalization of NCs is relatively low compared to larger particles
such as quantum dots [132] in the reticuloendothelial system (RES)—phagocytic cells that
clear the circulation and tissues from particles and soluble substances. However, in human
dendritic cells, AuNCs are internalized via the endocytic pathway more efficiently than the
larger AuNPs.
Importantly, when internalized, AuNCs might cause perturbations in the cellular
environment. Recently, a study on human primary astrocytes demonstrated that AuNCs
were not inert within the cells. Even though no significant cell loss has been observed for
AuNC concentrations below 10 µM, alterations were detected in the organellar and redox-
responsive transcription factor homeostasis [133]. These effects may also depend on the
nature of the ligands. For instance, the type of ligand may determine the type of immune
response in dendritic cells [130] as well as the state of intracellular redox signaling [131].
2.3.2. Biodistribution
Nanomaterials can reach and accumulate in tumors via passive and active targeting.
While active targeting depends on specific interactions between nanomaterials and tumors
(see Section 1.3.3), passive tumor targeting by nanomaterials precedes the active targeting
and is essential to create an opportunity for the occurrence of specific interactions. In-
deed, passive and preferential targeting of the tumors by both NPs and NCs have been
observed, and this phenomenon has been named the enhanced permeability and retention
effect (EPR) [132,134]. EPR can be explained by the presence of pores with sizes of up to
2000 nm within tumors [135]. These pores represent inter-endothelial gaps formed during
angiogenesis in the tumors, and they allow NPs to accumulate in cancer tissues at higher
concentrations than in normal tissues. Thus, this passive accumulation of NPs in tumors
takes advantage of the pathophysiological properties of the tumor tissue. Despite being the
foundation of tumor-targeted drug delivery and the NP accumulation principle, the EPR
effect in patients has been recently questioned [136,137]; the mechanism of entry of NPs into
solid tumors appears to be more intricate than considered earlier [138]. Either way, passive
tumor targeting by nanomaterials has certain disadvantages, such as arbitrary targeting,
inefficient dispersion of the NPs, and variability among different tumor types and different
patients [137]. Interestingly, the EPR effect is generally more pronounced in animal models
than in cancer patients, which hampers understanding of the NC biodistribution and
translation to clinic of the results obtained in animal studies.
The biodistribution of NPs and NCs is affected by their interaction with the environ-
ment, and this interaction differs for NPs and NCs. Upon administration, NPs are rapidly
exposed to protein-rich biological fluids. These proteins interact with the NPs and form
a protein corona on their surface [139]. Such protein coronas affect the size and charge
of the NPs [140] as well as their stability, dispersibility, pharmacokinetics, and toxicity
profiles [141]. Ultimately, the biodistribution of decorated NPs is altered, and they may
even get recognized by the immune system (RES). It has been demonstrated that the protein
corona promotes the cellular uptake of the NPs by the immune cells of the RES. To avoid
recognition by the immune system, PEGylation of the NPs was introduced, which resulted
in an increase in the blood circulation of the NPs as a side effect [142].
Currently, little is known about the nano–bio interactions of NCs, and it is still unclear
how they interact with proteins from the biological environment. Interestingly, Yin et al.
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showed that the conventional protein corona model in DHLA-liganded AuNCs does not
apply, and they coined the term “protein complex” for proteins bound to NCs [143]. More
studies are required to characterize the NC–protein interaction and its impact on the
biodistribution, cellular uptake, and cytotoxicity of the NCs.
The fine-tuning of nanomaterial biodistribution within tissues and cells can be achieved
by active targeting, as described in Section 1.3.3. A variety of ligands can be used for this
purpose, and they are usually small molecules that specifically interact with receptors
overexpressed at the surface of the tumor cells. Antibodies, aptamers, or peptides are
often used since they target proteins on the cell surface [74] and increase the probability of
endocytosis of the nanomaterials by tumor cells.
2.3.3. Toxicity and Clearance
Clinical application of the nanomaterials depends on their toxicity and clearance from
the body. Regarding the overall toxicity of nanomaterials, it is important to consider their
toxic effects both in vitro and in vivo. High toxicity in vitro (in the cell culture models) can
be counteracted in vivo by efficient clearance and vice versa.
The size, shape, surface properties, and chemical composition of the nanomaterials are
critical determinants of their toxicity and clearance [144]. However, the results of various
toxicological studies are controversial, making it difficult to derive straightforward conclusions.
While some researchers have shown that nanomaterials smaller than 5 nm (which include the
NCs) are more toxic than the larger ones, both in vitro [145–147] and in vivo, in the zebrafish
model [148], others have reported the opposite results in vivo [149–151].
Clearance mechanisms have been well described for NPs [152]. Three systems are
involved in the clearance of NPs. The first one is the RES, where macrophages phagocytose
large NPs (>6 nm), leading to extended retention (up to 6 months) of the partially digested
NPs in the body. The second clearance pathway is hepatobiliary excretion [153]. This
pathway is also utilized by NPs larger than 6 nm, and their retention, in this case, lasts
for up to a couple of weeks. The third elimination route is renal excretion, where the
glomerular capillary walls act as a filter for NPs smaller than 6 nm [154]. Renal clearance is
often preferred because of the fast and efficient removal of NPs (hours to days), especially
non-degradable noble metal NPs [152]. With their small size (<2nm), Au liganded NCs
are cleared in vivo through the renal system, which makes them excellent candidates for
clinical applications.
Given that the biological safety of nanomaterials depends on many intrinsic and
extrinsic factors, including their biological environment, toxicity must be evaluated for
each specific NC.
2.4. Structure, Optical Properties, and Functionalization of Quantum Nanoclusters
2.4.1. Structure of Quantum Nanoclusters
To synthesize AuNCs containing only several atoms, an appropriate combination
of parameters such as temperature, stabilizers, reduction method, and the initial ratio of
metal salt to stabilizer is needed. The atomic precision and molecular purity of AuNC
can be reached using size-focused methodology [155–157]. In addition, the use of ligands
is crucial not only for the stabilization of AuNCs but also for tailoring their fluorescent
properties. Suitable ligands with electron-rich atomic groups can enhance the fluorescence
of AuNCs due to the charge transfer between the ligands and the metal core [158]. Thiols
are commonly employed as ligands for noble metal NCs because of the strong affinity of
sulfur to noble metals, especially to gold. Moreover, thiol-containing molecules are good
stabilizers for AuNCs. Among thiols, GSH has played a key role in the production of
AuNCs [159–161].
A distinctive feature of atomically precise ligand-protected noble metal NCs is the
connection between their structure and their spectroscopic properties. The properties
of such NCs can be determined using experimental and theoretical approaches, which
provide complementary information. Different techniques, such as X-ray crystallography,
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mass spectrometry, X-ray powder diffraction (XRPD), and nuclear magnetic resonance
(NMR) spectroscopy, have been used for the characterization of AuNCs [45,123,162,163].
The structure of some NCs has been resolved experimentally by means of a single crystal
X-ray diffraction [123].
Theoretical approaches include density functional theory (DFT) and time-dependent
density functional theory (TDDFT), where a basic variable, the many-body wavefunction,
is replaced by a density function. The TDDFT approach allows the calculation of the pho-
toabsorption spectra for relatively large systems after the structural properties have been
determined by DFT. Despite significant approximations, these theoretical approaches are
useful for predictions of structural and optical properties of both protected and unprotected
NCs [164].
The combined experimental and theoretical findings resulted in a scheme depicting
the link between the structure and optical properties of the liganded AuNCs (Figure 3). In
that scheme (upper panel), the AuNC is presented as a multi-shell system that consists of
three components: a metal core, the metal–ligand interface with staple motifs, and surface
ligands. Surface thiolate ligands (SRs) do not just passivate the gold core but build staples
or semi-rings, Au(SR)2 (-RS-Au-RS) or Au2(SR)3 (-RS-Au-S(R)-Au-SR-), that bind to the core
surface and serve as its protection. The existence of three shells enables a ligand-to-metal
core charge transfer (LMCT) or ligand-to-metal metal charge transfer (LMMCT). In both
cases, communication can occur either through direct bonding or through the donation of
electron-rich ligand groups. NIR and visible absorption of AuNCs is always a consequence
of charge transfer, which occurs either due to metal–metal electron transitions or via LMCT
and LMMCT (Figure 3, bottom panel). For instance, Zhou and coworkers revealed that the
visible and NIR emissions of Au25 NCs originate from the surface state and Au13 core state,
respectively [165].




Figure 3. Diagram showing the view of liganded gold nanoclusters as multi-shell system on an ex-
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optical materials due to their remarkable NLO characteristics. SHG and/or TPA/TPEF pro-
cesses can reach the highest corresponding cross-sections by a rational design of “ligand–
core” templates and by controlling the NC size and/or asymmetry (Figure 4). A direct 
correlation between the structure and (multi)photonic properties of these nano-objects has 
been determined via experimental and theoretical investigations of the structure–prop-
erty relationship (Figure 5). The TPA cross-section of liganded noble metal NCs is several 
orders of magnitude larger than that of commercially available dyes. These enhanced 
NLO properties are due to a subtle balance between resonance effects (position of transi-
tions vs. laser excitation) and large transition dipole moments (due to ligand-to-core 
charge transfer character of excitations). On the other hand, the structure asymmetry (in-
herent to the metal core and/or brought by the asymmetric arrangement of surface lig-
ands) in NCs can boost the SHG process (sensitive to non-centrosymmetric systems) [166], 
as evidenced by the enhanced NLO properties of Au15SG13 [167].  
Figure 3. Diagram showing the view of liganded gold nanoclusters as multi-shell system on an
example of Au15(SCH3)13 (upper panel). TDDFT two-photon absorption spectrum (bottom left)
and molecular orbitals (bottom right) involved in transitions for an Au15(SCH3)13 nanocluster. The
upper scheme was adapted from [45] (p. 18). For theoretical methods used for the bottom panel,
see [113].
2.4.2. Qu tum Nanoclusters as Non-Lin ar Optical Probes
Liganded silver and gold NCs represent an emerging class of extremely interesting
optical materials due to their remarkable NLO characteristics. SHG and/or TPA/TPEF
pr cesses can r ach the highest corresponding cross-secti ns b a rational design of “ligand–
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core” templates and by controlling the NC size and/or asymmetry (Figure 4). A direct
correlation between the structure and (multi)photonic properties of these nano-objects has
been determined via experimental and theoretical investigations of the structure–property
relationship (Figure 5). The TPA cross-section of liganded noble metal NCs is several
orders of magnitude larger than that of commercially available dyes. These enhanced NLO
properties are due to a subtle balance between resonance effects (position of transitions vs.
laser excitation) and large transition dipole moments (due to ligand-to-core charge transfer
character of excitations). On the other hand, the structure asymmetry (inherent to the metal
core and/or brought by the asymmetric arrangement of surface ligands) in NCs can boost
the SHG process (sensitive to non-centrosymmetric systems) [166], as evidenced by the
enhanced NLO properties of Au15SG13 [167].
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properties of NCs towards the NIR region. Drugs, photosensitizers, or radiosensitizers 
can be used for functionalization for cancer therapy or as targeting molecules that interact 
specifically with receptors overexpressed at the surface of tumor cells. Such interfacial 
engineering of AuNCs for biomedical applications has been recently reviewed by Xie’s 
group [168]. One efficient approach to functionalization is a direct synthesis of AuNCs, 
with the molecule of interest containing a terminal thiol group that can bind to the metal 
surface. For instance, Le Guevel et al. [169] started with zwitterionic sulfobetaine-stabi-
lized AuNCs that have the capacity to accumulate in brain tumors. To further improve the 
tumor uptake of these AuNCs, they functionalized them with arginine, and the resulting 
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2.4.3. Functionalization of Quantum Nanoclusters
Functionalization is of crucial importance for creating tumor-biomarker-specific NCs
with optimal bio-compatible optical properties. One of the great advantages of NCs is
their suitability for efficient and controlled functionalization. Small organic molecules and
biomolecules are commonly added to he NC s rface as fluorophores to shift the optical
pr perties of NCs towards the NIR regi n. Drugs, photosensitize s, or radiosensitizers
can be used for functionalization for cancer therapy or as targeting molecules that interact
specifically with receptors overexpressed at the surface of tumor cells. Such interfacial
engineering of AuNCs for biomedical applications has been recently reviewed by Xie’s
group [168]. One efficient approach to functionalization is a direct synthesis of AuNCs,
with the molecule of interest containing a terminal thiol group that can bind to the metal
surface. For instance, Le Guevel et al. [169] started with zwitterionic sulfobetaine-stabilized
AuNCs that have the capacity to accumulate in brain tumors. To further improve the tumor
uptake of these AuNCs, they functionalized them with arginine, and the resulting AuSG-
2Arg exhibited r pid accumul tion in cancer cells, thus being potentially inte esting for
radiotherapy enhancement [170]. A second approach is based on the post-functionalization
of NCs, whereby click chemistry and succinimidyl ester reactions were used to covalently
bind molecules of interest to the protective ligand [125].
A third approach, the ligand exchange strategy, is based on the replacement of the
preexisting structural ligand with a specializing ligand containing a thiol group. The
ligand exchange strategy is possible due to the unique structural features of the NCs,
which can be prepared with atomic precision. This is in stark contrast to larger NPs, for
which the control of surface functionalization is not possible. In addition to adding specific
recognition properties to the NC, introducing a controlled number of functional ligand
molecules by a ligand exchange strategy can also boost NCs’ NLO properties. Indeed,
this ligand exchange will induce symmetry breaking in NCs, leading to efficient second-
order nonlinear scattering, in particular for SHG signals, as demonstrated by Verbiest and
colleagues [171]. Ligand shell engineering through ligand exchange can also increase the
stability of metal NCs’ surface and lead to rigidification effects, enhancing their fluorescence
properties [172,173]. The introduction of functional ligands through a ligand exchange
strategy may also enhance their non-linear photoluminescence through a subtle interplay
of metal–ligand interaction.
An example of a successfully applied ligand exchange strategy to introduce a specific
recognition moiety into NCs is a recent generation of thiolated aminooxy-functionalized
AuNCs, which can interact with protein carbonyls and be detected using optical methods
(Figure 6) [167]. Au15SG13 NCs were readily functionalized by one or several thiolated
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aminooxy molecules (3-(aminooxy)-1-propanethiol) via a ligand exchange procedure. The
as-prepared functionalized aminooxy-Au15 NCs were reacted with carbonylated proteins.
The targeted carbonylated proteins were then detected either by one-photon fluorescence
(with a fluorescence scanner) or by TPEF (with a multi-photon confocal microscope). Pro-
tein carbonylation at the molecular level on model lysozyme was validated by computation
chemistry to better evaluate the nature of binding between the NCs and the protein car-
bonyls (see Figure 4). Altogether, this is proof of principle that functionalized liganded
AuNCs can serve for the detection of carbonylation sites and might be more efficient than
organic dyes. Such rational design of novel functional bi-thiolate-protected metal NCs
with controllable surface chemistry could pave the way towards many similar practical
applications, particularly in the molecular diagnostics of cancer.




Figure 6. Detection of protein carbonyls using aminooxy-liganded AuNCs (top panel). Quantum 
mechanics/molecular mechanics (QM/MM) (two-layer ONIOM [174]) interacting with lysozyme. 
The interface between liganded cluster Au15(SG)12(3-(aminooxy)-1-propanethiol)1 and protein is en-
larged (right side), illustrating the aminooxy-serine oxyme bond and the hydrogen-bonding net-
work (SG—grey; Au—gold; S—magenta; lysozyme—green; oxyme bond—blue; h-bonds—dotted 
in red). Figure adapted from [167] (bottom panel). Au15-targeted carbonylated proteins detected on 
gels by fluorescence scanner (a) and multiphoton confocal imaging (b,c). Laser excitation was at 780 
nm, and emitted photons were detected with (b) visible range (350–700 nm) and (c) IR range (>850 
nm). Ellipses: Fixed concentration of 500 µM Au15(SG)12(3-(aminooxy)-1-propanethiol)1 was incu-
bated with a decreasing range of concentrations of the lysozyme (50–1 µM, corresponding to 5–0.1 
µg protein loaded in the gel). 
2.4.4. Application of the AuNCs in Cancer Diagnostics 
To date, numerous AuNCs have been developed for the detection of tumor bi-
omarkers such as the folate receptor, calreticulin, citrate, or the LHRH receptor (see Table 
2). While many of them have been studied in cell lines, there are examples where they 
have been tested in liquid biopsies such as human urine and even in vivo in mouse models 
of cancer. For instance, Cys-AuNCs have been used to indirectly quantify the amount of 
citrate—a biomarker of early stages of prostate cancer—in a colorimetric assay applied in 
human urine [97]. This assay is based on a citrate-mediated inhibition of the intrinsic pe-
roxidase-mimetic activity of Cys-AuNCs. Another example is an AuNC liganded with a 
tumor-targeting LHRH peptide and labeled with iodine-124, which has been used as a 
PET tracer for lung cancer in xenografted mice [74]. Even though AuNCs are still insuffi-
ciently explored, these and other similar studies pave the way for their future application 
in the clinical setting. 
3. Conclusions—Perspectives  
Various nanomaterials have been developed as tools of precision medicine for the 
detection of tumor biomarkers. Liganded metal nanomaterials such as NPs and NCs are 
Fi t ction of protein carbonyls using aminooxy-ligande AuNCs (top panel). Quant m
ec i molecular i s (QM/ ) (two-layer ONIOM [174]) interacting with lysozyme.
he interface bet een ligan e cl ster 15(S )12(3-(a inooxy)-1- ro anethiol)1 and protein is
enlarged (right side), illustrating the aminooxy-serine oxyme bond and the hydrogen-bonding
network (SG—grey; Au—gold; S—magenta; lysozyme—green; oxyme bond—blue; h-bonds—dotted
in red). Figure adapted from [167] (bottom panel). Au15-targeted carbonylated proteins detected
on gels by fluorescence scanner (a) and multiphoton confocal imaging (b,c). Laser excitation was
at 780 nm, and emitted photons were detected with (b) visible range (350–700 nm) and (c) IR range
(>850 nm). Ellipses: Fixed concentration of 500 µM Au15(SG)12(3-(aminooxy)-1-propanethiol)1 was
incubated with a decreasing range of concentrations of the lysozyme (50–1 µM, corresponding to
5–0.1 µg protein loaded in the gel).
2.4.4. lication of the AuNCs in Cancer Diagnostics
date, numerous AuNCs have been d velop d for the detec ion of umor bi markers
such as the folate rec ptor, calreticulin, citrate, or the LHRH eceptor (see Table 2). While
Cancers 2021, 13, 4206 20 of 28
many of them have been studied in cell lines, there are examples where they have been
tested in liquid biopsies such as human urine and even in vivo in mouse models of cancer.
For instance, Cys-AuNCs have been used to indirectly quantify the amount of citrate—a
biomarker of early stages of prostate cancer—in a colorimetric assay applied in human
urine [97]. This assay is based on a citrate-mediated inhibition of the intrinsic peroxidase-
mimetic activity of Cys-AuNCs. Another example is an AuNC liganded with a tumor-
targeting LHRH peptide and labeled with iodine-124, which has been used as a PET
tracer for lung cancer in xenografted mice [74]. Even though AuNCs are still insufficiently
explored, these and other similar studies pave the way for their future application in the
clinical setting.
3. Conclusions—Perspectives
Various nanomaterials have been developed as tools of precision medicine for the
detection of tumor biomarkers. Liganded metal nanomaterials such as NPs and NCs are
structurally highly versatile, thus providing numerous opportunities for specific applica-
tions. They can be adapted to detect different biomarkers and for visualization by different
imaging techniques through the selection of suitable specializing (biomarker recognition
moieties) and structural ligands, respectively. Given the increasing number of newly devel-
oped nanomaterials and options for their detection, the choice of a specific nanomaterial in
a desired application becomes a challenge. In this review, we have discussed atomically
precise ligand-protected noble metal NCs and their properties relevant for tumor biomarker
detection (summarized in Figure 7). They are characterized by non-linear optical properties
that are compatible with biological samples and allow for deep-tissue imaging. Moreover,
their functionalization can be precisely controlled. Finally, they can be rapidly eliminated
from the body via the renal clearance system. Together, these considerations emphasize the
value of NCs as tools in the molecular diagnostics of cancer.
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BRCA Breast cancer gene
CA 125 Cancer antigen 125
CA 19-9 Cancer antigen 19-9
CCR5 C-C chemokine receptor type 5
CEA Carcinoembryonic antigen
CT Computed tomography
CTC Circulating tumor cell
DFT Density functional theory
DHLA Bidentate dihydrolipoic acid
DLS Dynamic light scattering
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EPR Enhanced permeability and retention effect
erbB3 Erb-B2 Receptor Tyrosine Kinase 3
FDG 2-18F-fluorodeoxyglucose
GLUT1 Glucose transporter 1
GRPR Gastrin-releasing peptide receptor
GSH Glutathione
hCG Human chorionic gonadotropin
HER2 Human epidermal growth factor receptor 2
ICP-AES Inductively coupled plasma atomic emission spectroscopy
ICP-MS Inductively coupled plasma mass spectrometry
IR Infrared
L-DOPA l-3,4-dihydroxyphenylalanine
LMCT Ligand-to-metal core charge transfer
LMMCT Ligand to metal-metal charge transfer
LNGFR Low-affinity nerve growth factor receptor
MCAM Melanoma cell adhesion molecule
MCSP Melanoma-associated chondroitin sulfate proteoglycan
MMP9 Matrix metallopeptidase 9
MPA Mercaptopropionic acid







PD-L1 Programmed death-ligand 1
PEG Polyethylene glycol
PET Positron emission tomography
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PrPC Cellular prion protein
PSA Prostate-specific antigen
PSMA Prostate-specific membrane antigen
QM/MM Quantum mechanics/molecular mechanics
RES Reticulo-endothelial system
SERS Surface-enhanced Raman spectroscopy
SHG Second harmonic generation
SPECT Single-photon emission computed tomography
SPR Surface plasmon resonance
SR Surface thiolate ligands
TDDFT Time-dependent density functional theory
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